[The antiemetic action of tropisetron (Navoban) in the cytostatic treatment of neoplastic diseases].
The most frequent side effects of chemotherapy are nausea and vomiting. This issue is a clinical analysis of the protective effect of a 5HT3 antagonist (Navoban-R; Sandoz Pharma Ltd., Basel, Switzerland) against chemotherapy--induced emesis (especially with the most emetic cytostatics--cisplatin and dacarbazine). In the first day of treatment, Navoban demonstrates a control of emesis for 75% of patients and in the following days for 80% of patients. The nausea is more frequent than vomiting. The most frequent side effects of Navoban were: headache (75% of patients), dizziness (62% of patients) and tiredness (50% of patients). This drug is a good protective against chemotherapy induce emesis and is very easy to administer.